The FDA advisory panel has recommended Tamiflu, Roche Pharmaceuticals antivirals and GlaxoSmithKline’s Relenza should be updated to include information about new cases of abnormal behaviour in some consumers administered the vaccination.

The committee said that current prescribing information does not adequately explain the hundreds of reports of delirium, hallucinations and psychotic behaviour in patients administered the influenza drugs in Japan and the US.

Content Updated ( Monday, 26 November 2007 )